Novo Nordisk Introduces Ozempic in India
Novo Nordisk has officially launched Ozempic (injectable semaglutide) in India. This marks the availability of a widely used once-weekly GLP-1 receptor agonist for adults dealing with uncontrolled type 2 diabetes. The company stated that Ozempic® is designed to supplement diet and exercise, arriving at a crucial time for India, which is experiencing a surge in diabetes cases.
According to WHO's 2023-24 estimates, India has 101 million individuals living with diabetes. An additional 136 million are classified as prediabetic, and 254 million are affected by generalized obesity. These figures underscore the pressing need for effective treatment solutions. Health tracking apps like Shotlee can help monitor blood sugar levels and medication adherence.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Novo Nordisk India MD Vikrant Shrotriya pointed out that many patients face the dual challenge of diabetes and excess weight, making Ozempic a suitable therapeutic option. He also noted that the company is aware of India's socioeconomic realities. To improve accessibility, the medication has been priced at Rs 2,200 per week.